The stimulatory effects of caffeine with oseltamivir (Tamiflu®) on light-dark behavior and open-field behavior in mice

Neuroscience Letters

Volumn 469, Issue 2, 2010, Pages 184-188

  Uchiyama, Hidemori ^a   Toda, Akihisa ^b   Imoto, Masumi ^b   Nishimura, Satoko ^b   Kuroki, Hiroaki ^b   Soeda, Shinji ^c   Shimeno, Hiroshi ^c   Watanabe, Shigenori ^a   Eyanagi, Reiko ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b DAIICHI UNIVERSITY OF PHARMACY   (Japan)

^c FUKUOKA UNIVERSITY   (Japan)

Author keywords

Adenosine receptor; Caffeine; Dopamine receptor; Oseltamivir (Tamiflu )

Indexed keywords

ANIMALS; ANTIVIRAL AGENTS; CAFFEINE; DARKNESS; DOPAMINE ANTAGONISTS; EXPLORATORY BEHAVIOR; FLUMAZENIL; GABA MODULATORS; HALOPERIDOL; MALE; MICE; MOTOR ACTIVITY; NEUROTRANSMITTER AGENTS; OSELTAMIVIR; PYRIMIDINES; RANDOM ALLOCATION; RECEPTOR, ADENOSINE A1; RECEPTORS, ADENOSINE A2; RECEPTORS, DOPAMINE D2; RECEPTORS, GABA-A; TRIAZOLES; XANTHINES;

EID: 72749085023     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.11.069     Document Type: Article

References (30)

1. Antoniou K., Papadopoulou-Daifoti Z., Hyphantis T., Papathanasiou G., Bekris E., Marselos M., Panlilio L., Müller C.E., Goldberg S.R., and Ferré S. A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2 receptors. Psychopharmacology 183 (2005) 154-162
2. 2A adenosine receptors on sleep-waking patterns in rat. Drug Dev. Res. 37 (1996) 65-72
3. Blumstein L.K., and Crawley J.N. Further characterization of a simple, automated exploratory model for the anxiolytic effects of benzodiazepine. Pharmacol. Biochem. Behav. 18 (1983) 37-40
4. Daly J.M., and Fredholm B.B. Caffeine an atypical drug of dependence. Drug Alcohol Depend. 51 (1998) 199-206
5. 1 receptor antagonist an agonists in mice. Drug Dev. Res. 43 (1998) 54
6. El Yacoubi M., Ledent C., Ménard J.-F., Parmentier M., Costentin J., and Vaugeois J.-M. The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. Br. J. Pharmacol. 7 (2000) 1465-1473
7. 2A adenosine receptors antagonists. Psychopharmacology 148 (2000) 148-163
8. Fredholm B.B., Bättig K., Holmen J., Nehlig A., and Zvartau E.E. Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. Pharmacol. Rev. 51 (1999) 83-133
9. Gonzalez L.E., Ouagazzal A.M., and File S.E. Stimulation of benzodiazepine receptors in the dorsal hippocampus and median raphe reveals differential GABAergic control in two animal tests of anxiety. Eur. J. Neurosci. 10 (1998) 3673-3680
10. Imaizumi M., Miyazaki S., and Onodera K. Effects of xanthine derivatives in a light/dark test in mice and the contribution of adenosine receptors. Methods Find Exp. Clin. Pharmacol. 16 (1994) 639-644
11. ® and its carboxylate metabolite. Neurosci. Lett. 426 (2007) 54-58
12. Karcz-Kubicha M., Antoniou K., Terasmaa A., Quarta D., Solinas M., Justinova Z., Pezzola A., Reggio R., Müller C.E., Fuxe K., Goldberg S.R., Popoli P., and Ferré S. Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology 28 (2003) 1281-1291
13. Katims J.J., Annau Z., and Snyder S.H. Interactions in the behavioral effects of methylxanthines and adenosine derivatives. J. Pharmacol. Exp. Ther. 277 (1983) 167-173
14. A receptor. Nature 388 (1997) 674-678
15. Logan L., Seale T.W., and Carney J.M. Inherent differences in sensitivity to metylxanthines among inbred mice. Pharmacol. Biochem. Behav. 24 (1986) 1281-1286
16. Nehlig A., Daval J.L., and Debry G. Caffeine and the central nervous system: mechanism of action, biochemical, metabolic and psychostimulant effects. Brain Res. Rev. 17 (1992) 139-170
17. Nikodijevic O., and Jacobson K.A. Locomotor activity in mice during chronic treatment with caffeine and withdrawal. Pharmacol. Biochem. Behav. 44 (1993) 199-216
18. 2-selective adenosine agonists and antagonists: evidence for synergism and antagonism. J. Pharmacol. Exp. Ther. 259 (1991) 286-294
19. Ono H., Nagano Y., Matsunami N., Suqiyama S., Yamamoto S., and Tanabe M. Oseltamivir, an anti-influenza virus drug, produces hypothermia in mice. Bio. Pharm. Bull. (2008) 638-642
20. Quarta D., borycz J., Solinas M., Patkar K., Hockemeyer J., Ciruela F., Lluis C., Franco R., Woods A.S., Goldberg S.R., and Ferré S. Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmissio and N-methyl-D-aspartate receptor stimulation. J. Neurochem. 91 (2004) 873-880
21. 2A receptors on glutamate and dopamine release in the shell of the nucleus accumbens: effects of chronic caffeine exposure. J. Neurochem. 88 (2004) 1151-1158
22. 2A receptor in sleep promotion. Eur. J. Pharmacol. 351 (1998) 155-162
23. Satoh K., Nonaka R., Ogata A., Nakae D., and Uehara S. Effects of oseltamivir phosphate (Tamiflu) and its metabolite (GS4071) on monoamine neurotransmission in the rat brain. Biol. Pharm. Bull. 30 (2007) 1816-1818
24. Snyder S.H., Katims J.J., Annau Z., Bruns R.F., and Daly J.W. Adenosine receptors and behavioral avtions of methylxanthines. Proc. Natl. Acad. Sci. U.S.A. 78 (1981) 3260-3264
25. Solinas M., Ferré S., You Z.B., Karcz-Kubicha M., Popoli P., and Goldberg S.R. Caffeine induces dopamine and glutamate release in the shell of the nucleus accumbens. J. Neurosci. 22 (2002) 6321-6324
26. Svenningsson P., Nomikos G.G., and Fredholm B.B. Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B rat striatum following acute caffeine administration. J. Neurosci. 15 (1995) 7612-7624
27. Usami A., Sasaki T., Satoh N., Akiba T., Yokashima S., Fukuyama T., Yamatsuqu K., Kanaai M., Shibasaki M., Matsuki N., and Ikegaya Y. Oseltamivir enhances hippocampal network synchronization. J. Pharmacol. Sci. 106 (2008) 659-662
28. Waldeck B. Effect of caffeine on locomotor activity and central catecholamine mechanisms: a study with special reference to drug interaction. Acta. Pharmacol. Toxicol. 36 (1975) 1-23
29. Wise R.E., and Bozarth M.A. A psychomotor stimulant theory of addiction. Psychol. Rev. 94 (1987) 469-492
30. Yoshino T., Nisijima K., Shioda K., Yui K., and Kato S. Oseltamivir (Tamiflu) increases dopamine levels in the rat medial prefrontal cortex. Neurosci. Lett. 438 (2008) 67-69